… LY-CoV555 bound to the severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-… Prophylactic treatment with LY-CoV555 protected the upper and lower respiratory tracts …
… (10) LY-CoV555 was observed to bind to an epitope … (5, 20, 21) Based on the crystal structure, the LY-CoV555 epitope … of LY-CoV555 Fab complexes in which the LY-CoV555 Fab was …
… LY-CoV016). In addition, the L452R mutation in the B.1.429 lineage escapes LY-CoV555. Furthermore, we identify single amino acid changes that escape the combined LYCoV555+LY-…
Y Sun, M Ho - Antibody therapeutics, 2020 - academic.oup.com
… /LY-CoV555) for the treatment of mild-to-moderate COVID-19. This review outlines the development of neutralizing antibodies against SARS-CoV-… of SARS-CoV-2 and SARS-CoV might …
… combination of LY-CoV555 and LY-… LY-CoV555 monotherapy and placebo. Citation22 Preliminary results of the BLAZE-1 study, provided only for the comparison between LY-CoV555 …
… (mAb) bamlanivimab (LY-CoV555) prevents viral attachment … , showing that LY-CoV555 is ineffective against B.1.351 but is … bamlanivimab (LY-CoV555) using live SARS-CoV-2 isolates. …
Y Huang, H Sun, H Yu, S Li, Q Zheng… - Antibody …, 2020 - academic.oup.com
… Of these, LY-CoV555 is the first antibody to enter into phase 1 clinical trials in the world and the NAb CB6, termed as JS016 in the clinical trial, is in the steady progress of phase 1 in …
S Liu, T Huynh, CB Stauft, TT Wang… - Journal of Chemical …, 2021 - ACS Publications
… SARS-CoV-2 but failed to target the Kappa variant. Here, we focus on the drug LY-CoV555 that … LY-CoV555 recognizes an epitope site in the RBD overlapping the binding site of hACE2 …
… Mice treated with 2B04/47D11 or LY-CoV555 also showed greater virus breakthrough than … than the other mAb cocktails, and LY-CoV555 mAb treatment conferred virtually no protection …